ReviewDrugs & aging2009
Lipid-lowering therapy for the primary prevention of cardiovascular disease in the elderly: opportunities and challenges.
Review in Drugs & aging, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 15 citations in OpenAlex.
- Changes in cholesterol-lowering medications use over a decade in community-dwelling older adults.The Annals of pharmacotherapyTrial
- Age-Related Changes in Hepatic Function: An Update on Implications for Drug Therapy.Drugs & aging · 2015Review
- [Analysis of medications dispensed to control the main cardiovascular risks in the Murcia Region: are there gender differences?].Atencion primaria · 2014Article
- Impact of age and sex on primary preventive treatment for cardiovascular disease in the West Midlands, UK: cross sectional study.BMJ (Clinical research ed.) · 2012Article
- Validation of prescribing appropriateness criteria for older Australians using the RAND/UCLA appropriateness method.BMJ open · 2012Article
- Choosing targets for glycaemia, blood pressure and low-density lipoprotein cholesterol in elderly individuals with diabetes mellitus.Drugs & aging · 2011Article
- Lipid lowering for secondary prevention of cardiovascular disease in older adults.Drugs & aging · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Although HMG-CoA reductase inhibitors (statins) have been shown to reduce the risk of cardiovascular events in patients aged 65-80 years who have clinical cardiovascular disease, fewer data are available for elderly patients without cardiovascular disease. Treatment guidelines recommend a low-density lipoprotein cholesterol goal of <100 mg/dL for those with cardiovascular disease or diabetes mellitus but vary in their recommendations for primary prevention. Moderate-dose statins have been shown to be effective and safe in properly selected elderly patients up to the age of 80 years. High-dose statins have also been shown to be effective and reasonably safe in patients without significant co-morbidities up to the age of 75 years. With advancing age, the potential for benefit from cholesterol-lowering treatment needs to be weighed against the increasing risk of muscle and hepatic toxicity, as well as competing causes of morbidity and mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.